Goto Y, Tamachi H, Fusegawa Y, Nakaya N, Homma Y, Mikami M, Iori S, Yamazaki A
School of Medicine, Tokai University, Tokyo, Japan.
J Cardiovasc Pharmacol. 1991;18 Suppl 4:S45-50.
The purpose of this study was to investigate the effect of carvedilol on serum lipids in patients with mild-to-moderate essential hypertension. Twenty-one patients with blood pressure greater than or equal to 160/95 mm Hg after a 4-week placebo run-in period were initially given 10 mg of carvedilol once daily. The dose was increased to 20 mg after 4 weeks if the target blood pressure was not achieved. The duration of treatment was 12 weeks. After 12 weeks of administration, blood pressure and the pulse rate (PR) declined significantly (blood pressure from 173/105 to 142/91 mm Hg, p less than 0.001; PR from 74 to 67 beats/min, p less than 0.001); however, serum lipids [total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein (HDL), HDL2, and HDL3], lipoprotein fraction (alpha, pre-beta, and beta), apoprotein fraction (A-I, A-II, CII, CIII, and E), and atherogenic index [(total cholesterol - HDL cholesterol) divided by HDL cholesterol] were not altered significantly. There were no side effects reported during the trial. From these results, it can be concluded that carvedilol has no adverse effect on the coronary risk profile as reflected by lipid measurements, and is an efficacious, safe, well-tolerated antihypertensive drug in patients with mild-to-moderate hypertension.
本研究旨在探讨卡维地洛对轻至中度原发性高血压患者血脂的影响。在为期4周的安慰剂导入期后，21例血压大于或等于160/95 mmHg的患者开始每日服用1次10 mg卡维地洛。如果未达到目标血压，则在4周后将剂量增加至20 mg。治疗持续时间为12周。给药12周后，血压和脉搏率（PR）显著下降（血压从173/105降至142/91 mmHg，p<0.001；PR从74次/分钟降至67次/分钟，p<0.001）；然而，血脂[总胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白（HDL）、HDL2和HDL3]、脂蛋白组分（α、前β和β）、载脂蛋白组分（A-I、A-II、CII、CIII和E）以及致动脉粥样硬化指数[（总胆固醇-HDL胆固醇）除以HDL胆固醇]均无显著改变。试验期间未报告有副作用。从这些结果可以得出结论，卡维地洛对血脂测量所反映的冠状动脉风险状况没有不良影响，并且是一种对轻至中度高血压患者有效、安全且耐受性良好的抗高血压药物。
